Central nervous system (CNS) malignancies and intrathecal chemotherapy may contribute to the risk of CVT development, by, for example, increasing the brain tissue prothrombin levels, or by damaging the blood–brain barrier 11, 14. The gene discussed is F2; the disease is congenital vertical talus.